NASDAQ:CRSP (CRISPR Therapeutics)
About CRSP
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
CRISPR Therapeutics (NASDAQ: CRSP) Latest News

Investing Articles
2 cheap shares that could be takeover targets in 2025

Investing Articles
2 bold stock market ideas to consider for a Stocks and Shares ISA

Investing Articles
1 growth stock that could soar 105%, according to Wall Street experts

Investing Articles
1 growth stock that could skyrocket over the next 10 years

Investing Articles
After sliding 75%, this fascinating growth stock could be in bargain basement territory

Investing Articles
After a 76% share price crash, is this now a bargain basement growth stock?

Investing Articles
How I’d invest £500 monthly to target a £56,400 second income for life

Investing Articles
1 incredible growth stock I can’t find on the FTSE 100

Investing Articles
2 stocks to buy in the high potential gene editing space

Top Stocks
Best US stocks to consider buying in February
Investing Articles
39.5% below its target price, is this the most exciting growth stock?

Investing Articles
This growth stock jumped 77%! I think it can go much higher
1❯